Skip to main content
. 2019 Jul 5;9:579. doi: 10.3389/fonc.2019.00579

Figure 2.

Figure 2

Alectinib inhibits activity of ALK mutants in PC12 cells. (A,B) PC12 cells transiently transfected with either ALK-wt (1.5 μg) or ALK mutant variants as indicated (0.75 μg), were treated with increasing concentrations of either alectinib (A) or crizotinib (B) at 48 h post-transfection. ALK activation was measured by immunoblotting for pALK-Y1604. (C,D) Shows the total ALK levels (as a loading control) for (A,B), respectively.